ABVC BioPharma, Inc. (ABVC) is a Biotechnology company in the Healthcare sector, currently trading at $1.36. It has a SharesGrow Score of 42/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ABVC = $15.87 (+1066.9% from the current price, the stock appears undervalued).
Valuation: ABVC trades at a trailing Price-to-Earnings (P/E) of -3.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.03.
Financials: revenue is $795,950, +68.7%/yr average growth. Net income is $8M (loss), growing at +9.4%/yr. Net profit margin is -993.6% (negative). Gross margin is 100% (+29.5 pp trend).
Balance sheet: total debt is $3M against $11M equity (Debt-to-Equity (D/E) ratio 0.31, conservative). Current ratio is 0.41 (tight liquidity). Debt-to-assets is 16.5%. Total assets: $21M.
Analyst outlook: 0 / 1 analysts rate ABVC as buy (0%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 83/100 (Pass), Past 0/100 (Fail), Health 33/100 (Fail), Moat 50/100 (Partial), Future 20/100 (Fail), Income 10/100 (Fail).
